Opinion of the Transparency Council – donepezili hydrochloridum
At its meeting on 22 April 2025, the Transparency Council adopted opinion No. 68/2025 on the on the reimbursement of medicines containing the active substance donepezili hydrochloridum for indications, dosages, or methods of administration other than those specified in the Summary of Product Characteristics, i.e., dementia with Lewy bodies, dementia in the course of Parkinson’s disease